Toll Free: 1-888-928-9744

Trillium Therapeutics Inc. - Product Pipeline Review - 2014

Published: Aug, 2014 | Pages: 28 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Trillium Therapeutics Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Trillium Therapeutics Inc. - Product Pipeline Review - 2014', provides an overview of the Trillium Therapeutics Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Trillium Therapeutics Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Trillium Therapeutics Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Trillium Therapeutics Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Trillium Therapeutics Inc.'s pipeline products

Reasons to buy

- Evaluate Trillium Therapeutics Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Trillium Therapeutics Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Trillium Therapeutics Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Trillium Therapeutics Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Trillium Therapeutics Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Trillium Therapeutics Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Trillium Therapeutics Inc. Snapshot 5
Trillium Therapeutics Inc. Overview 5
Key Information 5
Key Facts 5
Trillium Therapeutics Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Trillium Therapeutics Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Trillium Therapeutics Inc. - Pipeline Products Glance 10
Trillium Therapeutics Inc. - Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
Trillium Therapeutics Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Trillium Therapeutics Inc. - Drug Profiles 12
tigecycline 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
TTI-1612 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
CD200-Specific Monoclonal Antibody 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
TTI-621 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
TTI-622 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Trillium Therapeutics Inc. - Pipeline Analysis 17
Trillium Therapeutics Inc. - Pipeline Products by Target 17
Trillium Therapeutics Inc. - Pipeline Products by Route of Administration 18
Trillium Therapeutics Inc. - Pipeline Products by Molecule Type 19
Trillium Therapeutics Inc. - Pipeline Products by Mechanism of Action 20
Trillium Therapeutics Inc. - Recent Pipeline Updates 21
Trillium Therapeutics Inc. - Dormant Projects 24
Trillium Therapeutics Inc. - Discontinued Pipeline Products 25
Discontinued Pipeline Product Profiles 25
(human chorionic gonadotropin-Beta + epoeitin alfa) 25
Trillium Therapeutics Inc. - Locations And Subsidiaries 26
Head Office 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 28
Disclaimer 28
List of Tables
Trillium Therapeutics Inc., Key Information 5
Trillium Therapeutics Inc., Key Facts 5
Trillium Therapeutics Inc. - Pipeline by Indication, 2014 7
Trillium Therapeutics Inc. - Pipeline by Stage of Development, 2014 8
Trillium Therapeutics Inc. - Monotherapy Products in Pipeline, 2014 9
Trillium Therapeutics Inc. - Phase I, 2014 10
Trillium Therapeutics Inc. - Preclinical, 2014 11
Trillium Therapeutics Inc. - Pipeline by Target, 2014 17
Trillium Therapeutics Inc. - Pipeline by Route of Administration, 2014 18
Trillium Therapeutics Inc. - Pipeline by Molecule Type, 2014 19
Trillium Therapeutics Inc. - Pipeline Products by Mechanism of Action, 2014 20
Trillium Therapeutics Inc. - Recent Pipeline Updates, 2014 21
Trillium Therapeutics Inc. - Dormant Developmental Projects,2014 24
Trillium Therapeutics Inc. - Discontinued Pipeline Products, 2014 25 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify